Independent Analyst update with details | ARWR Message Board Posts

Arrowhead Pharmaceuticals, Inc.

  ARWR website

ARWR   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  10001 of 10041  at  5/31/2019 1:05:52 PM  by

Aspector


 In response to msg 10000 by  Steve_382
view thread

Re: Independent Analyst update with details

Hi Steve,
I heard from BBS re your comment (I am posting here for him, as he is not an IV member):

I don't state that the ESC "platform drugs" are retired or obsolete. I state that the platform itself is retired or obsolete - that is a factual statement and is not disingenuous by any means. The ESC platform has already dropped 2 drugs, which is why they moved to ESC+. I clearly state on the webpage "current RNAi targets on obsolete RNAi platforms".
Lastly, knowing that the ESC platform is obsolete or retired is a very relevant piece of information and should specifically be pointed out. People should not think that Alnylam will develop any more drugs on that platform, but rather, just see what they have through.





     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 6     Views: 254
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
10002 Re: Independent Analyst update with details Steve_382 1 5/31/2019 7:53:58 PM


About Us  �  Contact Us  �  Follow Us on Twitter  �  Members Directory  �  Help Center  �  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
� 2003-2018 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...